Breast health encompasses awareness of normal breast tissue, recognition of changes, routine screening, and understanding of benign and malignant breast conditions. Breast cancer is the most common cancer in women (excluding skin cancer), with a lifetime risk of 1 in 8.

Breastfeeding — Breast health encompasses self-awareness, screening for breast cancer, and understanding benign breast conditions. Breast cancer is the most common cancer in women. Source: Unsplash.

Breast Self-Awareness

Current guidelines from ACOG and the American Cancer Society emphasize breast self-awareness rather than formal monthly self-examination. Women should be familiar with how their breasts normally look and feel and report any changes promptly. Clinical breast examination by a healthcare provider every 1-3 years for women aged 25-39 and annually for women 40+ is recommended.

Benign Breast Conditions

Contraception — Benign breast conditions include fibroadenomas, fibrocystic changes, and mastitis. Source: Unsplash.

Fibroadenomas

Fibroadenomas are the most common benign breast tumors in young women (peak age 20-30). They are solid, rubbery, well-circumscribed, mobile masses that are painless and hormonally sensitive (may grow during pregnancy or with hormonal contraception). They are benign and do not increase cancer risk (except complex fibroadenomas, which carry a slightly increased risk). Diagnosis is by ultrasound (probably fibroadenoma) with biopsy if atypical features. Management: observation unless large, growing, or symptomatic (surgical excision).

Fibrocystic Changes

Fibrocystic changes affect 50-60% of premenopausal women. Cyclical breast pain, nodularity, and cysts that fluctuate with the menstrual cycle. Management: supportive bras, caffeine reduction (limited evidence), NSAIDs for pain, and simple cyst aspiration if painful.

Mastitis and Breast Abscess

Mastitis (inflammation of breast tissue, usually infectious) occurs most commonly during lactation. Symptoms: localized breast pain, redness, warmth, swelling, and flu-like symptoms. Treatment: antibiotics (dicloxacillin, cephalexin), continued breastfeeding or pumping (milk is safe), and supportive care. Breast abscess requires drainage (needle aspiration or incision and drainage).

ⓘ Information

Nipple discharge is a common breast symptom but is rarely malignant. Key distinguishing features: pathologic discharge (spontaneous, unilateral, from a single duct, persistent, and clear, bloody, or serous) requires further evaluation. Physiologic discharge (bilateral, from multiple ducts, expressed/manual, milky or colored) is benign. Causes of pathologic discharge include intraductal papilloma (most common — benign), duct ectasia (dilation of ducts, benign), and rarely ductal carcinoma in situ (DCIS) or invasive cancer. Evaluation: physical exam, mammogram, ductal ultrasound, and may include ductography or MRI. Bloody discharge in women under 40 is usually benign (intraductal papilloma). The risk of malignancy increases in women over 50. Milky discharge (galactorrhea) in a non-pregnant, non-lactating woman should prompt evaluation of prolactin (check for pituitary adenoma) and thyroid function.

Breast Cancer Screening

Mammography is the cornerstone of breast cancer screening. The USPSTF recommends biennial mammography for women aged 50-74 (Grade B) and shared decision-making for women aged 40-49 (Grade C). The ACOG and ACS start annual mammograms at age 45 (ACS) or 40 (ACOG), transitioning to biennial at age 55. Women at high risk (BRCA1/2 mutation, strong family history, prior chest radiation) should start screening at age 30 with annual mammogram and breast MRI. MRI is not recommended for average-risk women.

Digital breast tomosynthesis (3D mammography) improves cancer detection and reduces recall rates compared to standard 2D mammography. Screening mammography reduces breast cancer mortality by 20-30% in women aged 40-74. The number needed to screen to prevent one breast cancer death is approximately 1,000-2,000.

Dense Breasts

About 40% of women have dense breast tissue (heterogeneously dense or extremely dense on mammography). Dense breasts reduce the sensitivity of mammography (cancer can hide in dense tissue) and are an independent risk factor for breast cancer (4-6 fold increase in extremely dense breasts). Many states require notification of women with dense breasts. Supplemental screening with ultrasound or MRI may be offered to women with dense breasts and additional risk factors — the evidence for routine supplemental screening in average-risk women with dense breasts is still evolving.

Breast Cancer

Risk Factors

Non-modifiable risk factors: female sex (99% of breast cancer), increasing age (median age 62), family history (1st-degree relative: 2-3 fold increase), genetic mutations (BRCA1 — 60-70% lifetime risk, BRCA2 — 45-55% lifetime risk, PALB2, TP53, PTEN, ATM, CHEK2), personal history of breast cancer (2-4 fold increased risk of contralateral), proliferative breast disease (atypical hyperplasia — 4-5 fold increase, LCIS), early menarche (under 12), late menopause (over 55), and dense breasts. Modifiable factors include nulliparity or first pregnancy after age 30, oral contraceptive use (slight increase, resolves after discontinuation), hormone therapy after menopause (combined estrogen-progestin increases risk), alcohol consumption (1 drink/day: 7-10% increase, 2-3 drinks/day: 20-30% increase), obesity (postmenopausal breast cancer), and physical inactivity.

Prevention

Preventive strategies include lifestyle modification (exercise, maintain healthy weight, limit alcohol), chemoprevention (tamoxifen or raloxifene for high-risk women — reduces risk by 50%), risk-reducing mastectomy (for BRCA carriers), risk-reducing salpingo-oophorectomy (for BRCA1/2 carriers — reduces risk by 50% for breast and 80-95% for ovarian cancer). Genetic counseling and testing for BRCA1/2 and other mutations is recommended for women with: personal or family history suggestive of hereditary breast cancer (Ashkenazi Jewish ancestry, ovarian cancer, male breast cancer, multiple breast cancers, triple-negative breast cancer under 60), or a known mutation in the family.

Diagnosis

The triple test: clinical breast exam, imaging (mammogram, ultrasound), and biopsy (core needle biopsy is preferred over fine needle aspiration). Biopsy is image-guided for non-palpable lesions and provides histologic diagnosis, receptor status (ER, PR, HER2), and grade. MRI is used for high-risk screening, pre-operative evaluation of extent of disease (in selected cases), and evaluation of occult primary breast cancer.

Treatment by Stage

Early-stage breast cancer (Stage I-III) involves a combination of surgery (breast-conserving surgery with radiation or mastectomy), sentinel lymph node biopsy or axillary lymph node dissection, radiation therapy (after breast-conserving surgery and for high-risk post-mastectomy patients), endocrine therapy (tamoxifen or aromatase inhibitors for ER+ cancers — typically 5-10 years), chemotherapy (for high-risk or triple-negative or HER2+ or > 0.5-1 cm tumors), and HER2-directed therapy (trastuzumab, pertuzumab, T-DM1) for HER2-positive cancers. Metastatic breast cancer (Stage IV) is incurable but treatable, with median survival of 3-5 years (longer for ER+ and HER2+, shorter for triple-negative).

Summary

Breast self-awareness and clinical breast exams are recommended. Mammography reduces breast cancer mortality by 20-30%. Breast cancer risk factors include age, genetics (BRCA, family history), reproductive history, and lifestyle. Benign conditions (fibroadenoma, fibrocystic changes, mastitis) are common and managed conservatively. Breast cancer treatment is personalized based on stage, receptor status, HER2 status, and genomic profiling. Multidisciplinary care — surgery, radiation, medical oncology, and supportive care — optimizes outcomes.